Serono May Pay $725 Million to End Probe

Swiss drugmaker Serono SA said it took a $725 million charge aimed at resolving a federal investigation into the marketing of its Serostim treatment for AIDS wasting. If the figure cited by the parent company of Serono Inc. of Rockland is finalized, it would be one of the largest amounts paid by any drugmaker as the Justice Department steps up its scrutiny of the sales and pricing practices of the pharmaceutical and biotechnology industries.
Big News Network